世界のペン型注射器市場は、2021年の376億ドルから2026年までに533億ドルに達し、予測期間中のCAGRは7.2％と予想されます。慢性疾患の有病率の増加、規制当局の承認数の増加、有利な保険適応と政府の支援、ペン型注射器の技術的進歩などが市場の成長を促す要因です。市場は成長しているものの、代替ドラッグデリバリーモード、開発途上地域における不利な保険適応シナリオ、針の不安といった要因が市場の成長を抑制する可能性があります。一方、針刺し損傷やペン型注射器の誤用が課題となります。しかし、この市場の事業機会は、生物製剤と新興市場の特許満了にあります。
糖尿病は、COVID-19患者の重症度と死亡に直接関連しています。炎症、凝固亢進、および免疫プロセスの障害に関連していることが示唆される罹患率および死亡率の増加がその証拠と見なされます。低血糖症と高血糖症はどちらも入院患者の有害転帰の予測因子です。糖尿病とSARS-CoV-2感染症の患者では、重症COVID-19のリスクを減らすために、最適な血糖コントロールが必要です。インスリンとGLP-1RAはどちらも、2型糖尿病患者に最適な血糖降下作用と抗炎症作用を示しており、無症候性で重症ではないCOVID-19糖尿病患者を治療するための有効な治療選択肢となる可能性があります。厳密な血糖モニタリングとインスリンまたは抗糖尿病薬の用量調整のために、糖尿病治療のためのカスタマイズされた治療法が必要になっています。糖尿病の綿密なモニタリングと最適な管理のために、インスリンペン、インスリンポンプ、持続血糖モニタリング装置の使用が増加しています。ペン型注射器は糖尿病の管理に大量に使用されています。したがって、これらは当然、製品およびサービスの全体的な需要の変化によって影響を受けます。
COVID-19のパンデミックがペン型注射器市場に与えた影響は大きなものではありませんでした。すでにさまざまな治療に注射ペンを使用している患者は、パンデミックの間も同じものを使用し続けました。しかし、ペン型注射器のサプライチェーンは、移動の制限、国境の閉鎖、および全体的な貿易の減少によって混乱しました。COVID-19に感染して治療を受けた患者は、糖尿病になるリスクが高くなります。したがって、糖尿病の発生率の上昇が、ペン型注射器の需要の増加につながるでしょう。
目次
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 27)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.3.3 CURRENCY
TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 32)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
2.2 MARKET SIZE ESTIMATION
FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 6 REVENUE SHARE ANALYSIS ILLUSTRATION: SANOFI
FIGURE 7 REVENUE ANALYSIS OF THE TOP FOUR COMPANIES: INJECTION PENS MARKET (2020)
FIGURE 8 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE INJECTION PENS MARKET (2021-2026)
FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 10 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 11 MARKET DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS FOR THE STUDY
2.6 RISK ASSESSMENT
TABLE 2 RISK ASSESSMENT: INJECTION PENS MARKET
2.7 LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.7.2 SCOPE-RELATED LIMITATIONS
3 EXECUTIVE SUMMARY (Page No. - 45)
FIGURE 12 INJECTION PENS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 13 INJECTION PENS MARKET, BY THERAPY, 2021 VS. 2026 (USD MILLION)
FIGURE 14 INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 15 INJECTION PENS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF THE INJECTION PENS MARKET
4 PREMIUM INSIGHTS (Page No. - 49)
4.1 INJECTION PENS MARKET OVERVIEW
FIGURE 17 GROWING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH
4.2 ASIA PACIFIC: INJECTION PENS MARKET, BY THERAPY AND COUNTRY (2020)
FIGURE 18 DIABETES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC INJECTION PENS MARKET IN 2020
4.3 INJECTION PENS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 19 CHINA TO REGISTER THE HIGHEST GROWTH RATE IN THE INJECTION PENS MARKET DURING THE FORECAST PERIOD
4.4 INJECTION PENS MARKET, BY REGION, 2021-2026
FIGURE 20 NORTH AMERICA WILL CONTINUE TO DOMINATE THE GLOBAL INJECTION PENS MARKET IN 2026
4.5 INJECTION PENS MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 53)
5.1 MARKET DYNAMICS
FIGURE 22 INJECTION PENS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.1.1 MARKET DRIVERS
5.1.1.1 Growing prevalence of chronic diseases
FIGURE 23 NUMBER OF PEOPLE WITH CHRONIC DISEASES IN THE US, 1995-2030 (MILLION INDIVIDUALS)
FIGURE 24 ESTIMATED DIABETIC POPULATION, BY REGION, 2019 VS. 2030 VS. 2040 (MILLION)
FIGURE 25 GLOBAL CANCER INCIDENCE, 2015-2040 (MILLION)
5.1.1.2 Increasing number of regulatory approvals
5.1.1.3 Favorable reimbursement and government support
5.1.1.4 Technological advancements in injection pens
TABLE 3 MARKET DRIVERS: IMPACT ANALYSIS
5.1.2 MARKET RESTRAINTS
5.1.2.1 Preference for alternative drug delivery modes
5.1.2.2 Poor reimbursement scenario in developing countries
5.1.2.3 Needle anxiety
TABLE 4 MARKET RESTRAINTS: IMPACT ANALYSIS
5.1.3 MARKET OPPORTUNITIES
5.1.3.1 Patent expiry of biologics to drive the demand for biosimilars
5.1.3.2 Growth opportunities in emerging markets
FIGURE 26 DIABETES POPULATION IN DEVELOPING COUNTRIES, 2020 VS. 2040 (MILLION)
TABLE 5 RISING INCOME LEVELS IN EMERGING COUNTRIES
TABLE 6 MARKET OPPORTUNITIES: IMPACT ANALYSIS
5.1.4 MARKET CHALLENGES
5.1.4.1 Needlestick injuries and misuse of injection pens
TABLE 7 MARKET CHALLENGES: IMPACT ANALYSIS
5.2 VALUE CHAIN ANALYSIS
FIGURE 27 INJECTION PENS MARKET: VALUE CHAIN ANALYSIS
5.3 SUPPLY CHAIN ANALYSIS
FIGURE 28 INJECTION PENS MARKET: SUPPLY CHAIN ANALYSIS
5.4 PRICING ANALYSIS
TABLE 8 PRICING OF INJECTION PENS AVAILABLE IN THE MARKET
5.5 ECOSYSTEM MARKET MAP
FIGURE 29 INJECTION PENS MARKET: ECOSYSTEM MARKET MAP
5.6 PORTER’S FIVE FORCES ANALYSIS
TABLE 9 INJECTION PENS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.6.1 INTENSITY OF COMPETITIVE RIVALRY
5.6.2 BARGAINING POWER OF SUPPLIERS
5.6.3 BARGAINING POWER OF BUYERS
5.6.4 THREAT OF SUBSTITUTES
5.6.5 THREAT OF NEW ENTRANTS
5.7 REGULATORY ANALYSIS
5.7.1 NORTH AMERICA
5.7.1.1 US
TABLE 10 US FDA: MEDICAL DEVICE CLASSIFICATION
TABLE 11 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
5.7.1.2 Canada
TABLE 12 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
FIGURE 30 CANADA: CLASS II MEDICAL DEVICE APPROVAL PROCESS
5.7.2 EUROPE
FIGURE 31 EUROPE: CE APPROVAL PROCESS FOR CLASS IIA MEDICAL DEVICES
5.7.3 ASIA PACIFIC
5.7.3.1 Japan
TABLE 13 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
5.7.3.2 China
TABLE 14 CHINA: REGULATORY BODIES APPOINTED FOR MEDICAL DEVICE APPROVAL
TABLE 15 CHINA: CLASSIFICATION OF MEDICAL DEVICES
5.7.3.3 India
5.8 IMPACT OF COVID-19 ON THE INJECTION PENS MARKET
5.9 PATENT ANALYSIS
5.9.1 PATENT PUBLICATION TRENDS FOR INJECTION PENS
FIGURE 32 PATENT PUBLICATION TRENDS (JANUARY 2011-SEPTEMBER 2021)
5.9.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
FIGURE 33 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR INJECTION PEN PATENTS (JANUARY 2011-SEPTEMBER 2021)
FIGURE 34 TOP APPLICANT COUNTRIES/REGIONS FOR INJECTION PEN PATENTS (JANUARY 2011-SEPTEMBER 2021)
5.10 TECHNOLOGY ANALYSIS
TABLE 16 PEN INJECTORS CLASSIFICATION
5.10.1 KEY TECHNOLOGIES
5.10.1.1 Dose setting and needle actuation
5.10.1.2 Pen injector material
5.10.2 COMPLEMENTARY TECHNOLOGIES
5.10.2.1 In-built dose and time log
5.10.2.2 Wireless connectivity
5.10.2.3 Smartpen injectors
5.10.2.4 Smart caps and attachments
5.10.2.5 Injector temperature monitoring
5.10.3 ADJACENT TECHNOLOGIES
5.10.3.1 Autoinjectors
5.10.3.2 Insulin pumps
6 INJECTION PENS MARKET, BY TYPE (Page No. - 79)
6.1 INTRODUCTION
TABLE 17 INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
6.2 DISPOSABLE INJECTION PENS
6.2.1 HIGH PATIENT COMPLIANCE AND EASE OF HANDLING TO DRIVE THE ADOPTION OF DISPOSABLE INJECTION PENS
TABLE 18 DISPOSABLE INJECTION PENS AVAILABLE IN THE MARKET
TABLE 19 DISPOSABLE INJECTION PENS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.3 REUSABLE INJECTION PENS
6.3.1 REUSABLE INJECTION PENS TO REGISTER THE HIGHEST GROWTH DUE TO TECHNOLOGICAL ADVANCEMENTS
TABLE 20 REUSABLE INJECTION PENS AVAILABLE IN THE MARKET
TABLE 21 REUSABLE INJECTION PENS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
7 INJECTION PENS MARKET, BY THERAPY (Page No. - 84)
7.1 INTRODUCTION
TABLE 22 INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
7.2 DIABETES
TABLE 23 INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 24 INJECTION PENS MARKET FOR DIABETES THERAPY, BY COUNTRY, 2019-2026 (USD MILLION)
7.2.1 INSULIN
7.2.1.1 Rising prevalence of diabetes is driving the growth of this market
TABLE 25 EXAMPLES OF INSULIN INJECTION PENS
TABLE 26 INJECTION PENS MARKET FOR INSULIN THERAPY, BY COUNTRY, 2019-2026 (USD MILLION)
7.2.2 GLUCAGON-LIKE PEPTIDE-1 (GLP-1) THERAPY
7.2.2.1 Strong focus of major pharmaceutical companies to introduce GLP-1 drugs to drive market growth
TABLE 27 EXAMPLES OF GLP-1 INJECTION PENS
TABLE 28 INJECTION PENS MARKET FOR GLP-1 THERAPY, BY COUNTRY, 2019-2026 (USD MILLION)
7.3 GROWTH HORMONE THERAPY
7.3.1 DEVELOPMENT OF SUSTAINED-RELEASE GROWTH HORMONE FORMULATIONS FOR REDUCING INJECTION FREQUENCY TO RESTRAIN THE MARKET GROWTH
TABLE 29 EXAMPLES OF INJECTION PENS FOR GROWTH HORMONE THERAPY
TABLE 30 INJECTION PENS MARKET FOR GROWTH HORMONE THERAPY, BY COUNTRY, 2019-2026 (USD MILLION)
7.4 OSTEOPOROSIS
7.4.1 GROWING PREVALENCE OF OSTEOPOROSIS IN GERIATRIC PATIENTS AND WOMEN TO DRIVE MARKET GROWTH
TABLE 31 EXAMPLES OF INJECTION PENS FOR OSTEOPOROSIS THERAPY
TABLE 32 INJECTION PENS MARKET FOR OSTEOPOROSIS THERAPY, BY COUNTRY, 2019-2026 (USD MILLION)
7.5 FERTILITY
7.5.1 DECREASE IN FERTILITY RATE HAS RESULTED IN THE INCREASED USE OF INJECTION PENS
TABLE 33 EXAMPLES OF INJECTION PENS FOR FERTILITY THERAPY
TABLE 34 INJECTION PENS MARKET FOR FERTILITY THERAPY, BY COUNTRY, 2019-2026 (USD MILLION)
7.6 CANCER
7.6.1 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH
TABLE 35 EXAMPLES OF INJECTION PENS FOR CANCER THERAPY
TABLE 36 INJECTION PENS MARKET FOR CANCER THERAPY, BY COUNTRY, 2019-2026 (USD MILLION)
7.7 AUTOIMMUNE DISEASES
7.7.1 DEVELOPMENTS IN THERAPIES AND DELIVERY DEVICES FOR THE TREATMENT OF MS TO BOOST THE MARKET GROWTH
TABLE 37 EXAMPLES OF INJECTION PENS FOR MULTIPLE SCLEROSIS AND PSORIASIS THERAPY
TABLE 38 INJECTION PENS MARKET FOR AUTOIMMUNE DISEASE THERAPY, BY COUNTRY, 2019-2026 (USD MILLION)
7.8 OTHER THERAPIES
TABLE 39 INJECTION PENS MARKET FOR OTHER THERAPIES, BY COUNTRY, 2019-2026 (USD MILLION)
8 INJECTION PENS MARKET, BY END USER (Page No. - 100)
8.1 INTRODUCTION
TABLE 40 INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
8.2 HOME CARE SETTINGS
8.2.1 HOME CARE SETTINGS ARE THE LARGEST END USERS OF INJECTION PENS
TABLE 41 INJECTION PENS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2019-2026 (USD MILLION)
8.3 HOSPITALS & CLINICS
8.3.1 GROWING INCIDENCE OF NEEDLESTICK INJURIES AND UNSAFE INJECTION PRACTICES HAVE INCREASED THE DEMAND FOR INJECTION PENS
TABLE 42 INJECTION PENS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2019-2026 (USD MILLION)
9 INJECTION PENS MARKET, BY REGION (Page No. - 105)
9.1 INTRODUCTION
TABLE 43 INJECTION PENS MARKET, BY REGION, 2019-2026 (USD MILLION)
FIGURE 35 EMERGING COUNTRIES ARE EXPECTED TO WITNESS HIGHER GROWTH IN THE FORECAST PERIOD
9.2 NORTH AMERICA
FIGURE 36 NORTH AMERICA: INJECTION PENS MARKET SNAPSHOT
TABLE 44 INJECTION PENS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 45 NORTH AMERICA: INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 46 NORTH AMERICA: INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 47 NORTH AMERICA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 48 NORTH AMERICA: INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.2.1 US
9.2.1.1 The US dominates the North American injection pens market
FIGURE 37 TOTAL FERTILITY RATE IN THE US POPULATION (1990-2020)
TABLE 49 US: KEY MACROINDICATORS
TABLE 50 US: INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 51 US: INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 52 US: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 53 US: INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Unfavorable regulatory processes in Canada to restrain the market growth
TABLE 54 CANADA: KEY MACROINDICATORS
TABLE 55 CANADA: INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 56 CANADA: INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 57 CANADA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 58 CANADA: INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.3 EUROPE
TABLE 59 EUROPE: INJECTION PENS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 60 EUROPE: INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 61 EUROPE: INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 62 EUROPE: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 63 EUROPE: INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 High diabetes expenditure and reimbursement for injection pens to drive the market in Germany
TABLE 64 GERMANY: KEY MACROINDICATORS
TABLE 65 GERMANY: INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 66 GERMANY: INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 67 GERMANY: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 68 GERMANY: INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.3.2 FRANCE
9.3.2.1 Misuse of injection pens pose a threat to the growth of this market
TABLE 69 FRANCE: KEY MACROINDICATORS
TABLE 70 FRANCE: INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 71 FRANCE: INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 72 FRANCE: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 73 FRANCE: INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.3.3 UK
9.3.3.1 NHS support and access to cost-effective injection pens are likely to drive the market in the UK
TABLE 74 UK: KEY MACROINDICATORS
TABLE 75 UK: INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 76 UK: INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 77 UK: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 78 UK: INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.3.4 ITALY
9.3.4.1 Regional variation in terms of coverage and benefits to hinder the market growth
TABLE 79 ITALY: KEY MACROINDICATORS
TABLE 80 ITALY: INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 81 ITALY: INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 82 ITALY: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 83 ITALY: INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.3.5 SPAIN
9.3.5.1 Supportive regulations mandating the use of safety injection pens to boost the growth of the Spanish market
TABLE 84 SPAIN: KEY MACROINDICATORS
TABLE 85 SPAIN: INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 86 SPAIN: INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 87 SPAIN: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 88 SPAIN: INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.3.6 BENELUX
9.3.6.1 Increasing awareness about injection pen devices to drive market growth
TABLE 89 BENELUX: INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 90 BENELUX: INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 91 BENELUX: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 92 BENELUX: INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.3.7 REST OF EUROPE
TABLE 93 ROE: INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 94 ROE: INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 95 ROE: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 96 ROE: INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 38 ASIA PACIFIC: INJECTION PENS MARKET SNAPSHOT
TABLE 97 APAC: INJECTION PENS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 98 APAC: INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 99 APAC: INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 100 APAC: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 101 APAC: INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.4.1 JAPAN
9.4.1.1 High diabetes incidence and supportive reimbursement policies to drive the market growth in Japan
TABLE 102 JAPAN: KEY MACROINDICATORS
TABLE 103 JAPAN: INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 104 JAPAN: INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 105 JAPAN: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 106 JAPAN: INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.4.2 CHINA
9.4.2.1 Large patient population and healthcare infrastructure improvements to drive the market growth in China
TABLE 107 CHINA: KEY MACROINDICATORS
TABLE 108 CHINA: INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 109 CHINA: INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 110 CHINA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 111 CHINA: INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Rising prevalence of obesity to drive market growth
TABLE 112 INDIA: KEY MACROINDICATORS
TABLE 113 INDIA: INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 114 INDIA: INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 115 INDIA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 116 INDIA: INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.4.4 SOUTHEAST ASIA
9.4.4.1 Growing awareness about diabetes to drive the adoption of injection pens
FIGURE 39 DIABETES PREVALENCE IN SOUTHEAST ASIA (2019)
FIGURE 40 HEALTHCARE EXPENDITURE (% OF GDP) IN SOUTHEAST ASIA (2018)
FIGURE 41 GERIATRIC POPULATION (% OF THE TOTAL POPULATION), 2019
TABLE 117 SOUTHEAST ASIA: INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 118 SOUTHEAST ASIA: INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 119 SOUTHEAST ASIA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 120 SOUTHEAST ASIA: INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.4.5 REST OF APAC
TABLE 121 ROAPAC: INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 122 ROAPAC: INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 123 ROAPAC: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 124 ROAPAC: INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.5 LATIN AMERICA
TABLE 125 LATAM: INJECTION PENS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 126 LATAM: INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 127 LATAM: INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 128 LATAM: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 129 LATAM: INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.5.1 BRAZIL
9.5.1.1 Brazil dominates the injection pens market in Latin America
TABLE 130 BRAZIL: KEY MACROINDICATORS
TABLE 131 BRAZIL: INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 132 BRAZIL: INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 133 BRAZIL: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 134 BRAZIL: INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.5.2 MEXICO
9.5.2.1 Increasing incidence of lifestyle-related disorders to drive market growth in Mexico
TABLE 135 MEXICO: KEY MACROINDICATORS
TABLE 136 MEXICO: INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 137 MEXICO: INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 138 MEXICO: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 139 MEXICO: INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.5.3 REST OF LATIN AMERICA
FIGURE 42 HEALTH EXPENDITURE (% OF GDP) IN LATIN AMERICAN COUNTRIES, 2018
TABLE 140 ROLATAM: INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 141 ROLATAM: INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 142 ROLATAM: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 143 ROLATAM: INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.6 MIDDLE EAST & AFRICA
9.6.1 INITIATIVES TO ENHANCE HEALTHCARE ACCESSIBILITY TO SUPPORT MARKET GROWTH
TABLE 144 MEA: INJECTION PENS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 145 MEA: INJECTION PENS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 146 MEA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019-2026 (USD MILLION)
TABLE 147 MEA: INJECTION PENS MARKET, BY END USER, 2019-2026 (USD MILLION)
10 COMPETITIVE LANDSCAPE (Page No. - 162)
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES
10.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
FIGURE 43 REVENUE ANALYSIS OF THE TOP PLAYERS IN THE INJECTION PENS MARKET
10.4 MARKET SHARE ANALYSIS
FIGURE 44 INJECTION PENS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
10.5 MARKET RANKING ANALYSIS OF OEM COMPANIES
FIGURE 45 INJECTION PENS MARKET RANKING, BY OEM COMPANY (2020)
10.6 COMPANY EVALUATION QUADRANT
10.6.1 STARS
10.6.2 EMERGING LEADERS
10.6.3 PERVASIVE PLAYERS
10.6.4 PARTICIPANTS
FIGURE 46 INJECTION PENS MARKET: COMPANY EVALUATION QUADRANT (2020)
10.7 COMPANY EVALUATION QUADRANT FOR START-UPS
10.7.1 PROGRESSIVE COMPANIES
10.7.2 DYNAMIC COMPANIES
10.7.3 STARTING BLOCKS
10.7.4 RESPONSIVE COMPANIES
FIGURE 47 INJECTION PENS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS (2020)
10.8 COMPANY PRODUCT FOOTPRINT
TABLE 148 PRODUCT PORTFOLIO ANALYSIS: INJECTION PENS MARKET, BY TYPE
TABLE 149 PRODUCT PORTFOLIO ANALYSIS: INJECTION PENS MARKET, BY THERAPY
10.9 GEOGRAPHIC FOOTPRINT OF MAJOR PLAYERS IN THE INJECTION PENS MARKET
TABLE 150 GEOGRAPHIC REVENUE MIX: INJECTION PENS MARKET (2020)
10.10 COMPETITIVE SCENARIO
10.10.1 PRODUCT LAUNCHES
TABLE 151 PRODUCT LAUNCHES (JANUARY 2018-SEPTEMBER 2021)
10.10.2 OTHER DEVELOPMENTS
TABLE 152 OTHER DEVELOPMENTS (JANUARY 2018-SEPTEMBER 2021)
11 COMPANY PROFILES (Page No. - 176)
11.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View)*
11.1.1 NOVO NORDISK A/S
TABLE 153 NOVO NORDISK A/S: BUSINESS OVERVIEW
FIGURE 48 NOVO NORDISK A/S: COMPANY SNAPSHOT (2020)
11.1.2 BECTON, DICKINSON AND COMPANY
TABLE 154 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 49 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
11.1.3 YPSOMED HOLDING AG
TABLE 155 YPSOMED HOLDING AG: BUSINESS OVERVIEW
FIGURE 50 YPSOMED HOLDING AG: COMPANY SNAPSHOT (2020)
11.1.4 SANOFI
TABLE 156 SANOFI: BUSINESS OVERVIEW
FIGURE 51 SANOFI: COMPANY SNAPSHOT (2020)
11.1.5 ELI LILLY AND COMPANY
TABLE 157 ELI LILLY AND COMPANY: BUSINESS OVERVIEW
FIGURE 52 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2020)
11.1.6 MERCK KGAA
TABLE 158 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 53 MERCK KGAA: COMPANY SNAPSHOT (2020)
11.1.7 ASTRAZENECA
TABLE 159 ASTRAZENECA: BUSINESS OVERVIEW
FIGURE 54 ASTRAZENECA: COMPANY SNAPSHOT (2020)
11.1.8 F. HOFFMANN-LA ROCHE LTD.
TABLE 160 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 55 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
11.1.9 OWEN MUMFORD
TABLE 161 OWEN MUMFORD: BUSINESS OVERVIEW
11.1.10 SULZER LTD.
TABLE 162 SULZER LTD.: BUSINESS OVERVIEW
11.1.11 SUN PHARMACEUTICAL INDUSTRIES LTD.
TABLE 163 SUN PHARMACEUTICAL INDUSTRIES LTD: BUSINESS OVERVIEW
FIGURE 56 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2020)
11.1.12 PFIZER
TABLE 164 PFIZER: BUSINESS OVERVIEW
FIGURE 57 PFIZER: COMPANY SNAPSHOT (2020)
11.1.13 BIOCON LTD.
TABLE 165 BIOCON LTD.: BUSINESS OVERVIEW
FIGURE 58 BIOCON LTD.: COMPANY SNAPSHOT (2020)
11.1.14 LUPIN LTD.
TABLE 166 LUPIN LTD.: BUSINESS OVERVIEW
FIGURE 59 LUPIN LTD.: COMPANY SNAPSHOT (2020)
11.1.15 WOCKHARDT LTD.
TABLE 167 WOCKHARDT LTD.: BUSINESS OVERVIEW
FIGURE 60 WOCKHARDT LTD.: COMPANY SNAPSHOT (2020)
11.1.16 APTARGROUP, INC.
TABLE 168 APTARGROUP, INC.: BUSINESS OVERVIEW
FIGURE 61 APTARGROUP, INC.: COMPANY SNAPSHOT (2020)
11.1.17 NOVARTIS AG
TABLE 169 NOVARTIS AG: BUSINESS OVERVIEW
FIGURE 62 NOVARTIS AG: COMPANY SNAPSHOT (2020)
11.1.18 GERRESHEIMER AG
TABLE 170 GERRESHEIMER AG: BUSINESS OVERVIEW
FIGURE 63 GERRESHEIMER AG: COMPANY SNAPSHOT (2020)
11.2 OTHER PLAYERS
11.2.1 SHAILY ENGINEERING PLASTICS LTD.
TABLE 171 SHAILY ENGINEERING PLASTICS LTD.: BUSINESS OVERVIEW
11.2.2 BESPAK EUROPE LTD.
TABLE 172 BESPAK EUROPE LTD.: BUSINESS OVERVIEW
11.2.3 SHL MEDICAL AG
TABLE 173 SHL MEDICAL AG: BUSINESS OVERVIEW
11.2.4 EMPERRA GMBH
TABLE 174 EMPERRA GMBH: BUSINESS OVERVIEW
11.2.5 NEMERA FRANCE SAS
TABLE 175 NEMERA FRANCE SAS: BUSINESS OVERVIEW
11.2.6 COMPANION MEDICAL, INC.
TABLE 176 COMPANION MEDICAL, INC.: BUSINESS OVERVIEW
11.2.7 JIANGSU DELFU MEDICAL DEVICE CO., LTD.
TABLE 177 JIANGSU DELFU MEDICAL DEVICE CO., LTD.: BUSINESS OVERVIEW
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
12 APPENDIX (Page No. - 223)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
